Lloyd K. Everson

1.8k total citations · 1 hit paper
30 papers, 1.5k citations indexed

About

Lloyd K. Everson is a scholar working on Oncology, Epidemiology and Cancer Research. According to data from OpenAlex, Lloyd K. Everson has authored 30 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 6 papers in Epidemiology and 6 papers in Cancer Research. Recurrent topics in Lloyd K. Everson's work include Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (6 papers) and Estrogen and related hormone effects (4 papers). Lloyd K. Everson is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Breast Cancer Treatment Studies (6 papers) and Estrogen and related hormone effects (4 papers). Lloyd K. Everson collaborates with scholars based in United States and Canada. Lloyd K. Everson's co-authors include James E. Krook, Stephen A. Cullinan, J A Mailliard, John A. Laurie, C G Moertel, Harry S. Wieand, M. J. OʼConnell, Michael A. Poon, Loren K. Tschetter and Shaun Ruddy and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Lloyd K. Everson

27 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

1989 725 citations Michael A. Poon, M. J. OʼConnell et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lloyd K. Everson United States	16	978	382	236	222	195	30	1.5k
Martin Poleski United States	12	548 0.6×	192 0.5×	289 1.2×	176 0.8×	193 1.0×	18	1.2k
T Buroker United States	18	835 0.9×	531 1.4×	603 2.6×	170 0.8×	96 0.5×	21	1.4k
V. Izraël France	16	946 1.0×	325 0.9×	259 1.1×	298 1.3×	311 1.6×	37	1.4k
H. Y. Yap United States	19	933 1.0×	451 1.2×	164 0.7×	292 1.3×	535 2.7×	42	1.4k
John D. Bonnet United States	22	1.0k 1.0×	264 0.7×	202 0.9×	147 0.7×	127 0.7×	41	1.7k
H Lambert United Kingdom	19	473 0.5×	232 0.6×	575 2.4×	316 1.4×	175 0.9×	50	1.7k
Daniela Kandioler Austria	23	835 0.9×	350 0.9×	351 1.5×	226 1.0×	529 2.7×	55	1.7k
M Krulik France	20	1.4k 1.4×	571 1.5×	329 1.4×	348 1.6×	79 0.4×	115	2.0k
Andy Sherrod United States	20	786 0.8×	525 1.4×	225 1.0×	283 1.3×	109 0.6×	39	1.6k
Rose J. Papac United States	19	647 0.7×	377 1.0×	342 1.4×	136 0.6×	164 0.8×	49	1.5k

Countries citing papers authored by Lloyd K. Everson

Since Specialization

Citations

This map shows the geographic impact of Lloyd K. Everson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lloyd K. Everson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lloyd K. Everson more than expected).

Fields of papers citing papers by Lloyd K. Everson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lloyd K. Everson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lloyd K. Everson. The network helps show where Lloyd K. Everson may publish in the future.

Co-authorship network of co-authors of Lloyd K. Everson

This figure shows the co-authorship network connecting the top 25 collaborators of Lloyd K. Everson. A scholar is included among the top collaborators of Lloyd K. Everson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lloyd K. Everson. Lloyd K. Everson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bosserman, Linda D., Lloyd K. Everson, & Armin D. Weinberg. (2012). Embracing the ‘new normal’. Community Oncology. 9(1). 31–33. 1 indexed citations

Everson, Lloyd K.. (1993). Cancer Program Development in the 1990s. Oncology Issues. 8(2). 8–10.

McLaren, Gordon D., et al.. (1992). Solitary cerebellar metastasis from transitional cell carcinoma of bladder. Urology. 40(1). 50–53. 13 indexed citations

Jett, James R., Lloyd K. Everson, Terry M. Therneau, et al.. (1990). Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.. Journal of Clinical Oncology. 8(1). 33–38. 47 indexed citations

Ingle, James N., James E. Krook, Daniel J. Schaid, et al.. (1990). Evaluation of Trilostane Plus Hydrocortisone in Women with Metastatic Breast Cancer and Prior Hormonal Therapy Exposure. American Journal of Clinical Oncology. 13(2). 93–97. 5 indexed citations

Everson, Lloyd K., James R. Jett, Judith R. OʼFallon, et al.. (1989). Alternating Chemotherapy With or Without VP-16 in Extensive-Stage Small-Cell Lung Cancer. American Journal of Clinical Oncology. 12(4). 339–344. 8 indexed citations

Edmonson, J H, Harry S. Wieand, J. W. Kugler, et al.. (1989). Cyclophosphamide-Cisplatin Versus Cyclophosphamide-Carboplatin in Stage III-IV Ovarian Carcinoma: A Comparison of Equally Myelosuppressive Regimens. JNCI Journal of the National Cancer Institute. 81(19). 1500–1504. 44 indexed citations

Ingle, James N., Lloyd K. Everson, Harry S. Wieand, et al.. (1989). Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer. Cancer. 63(7). 1257–1264. 24 indexed citations

Buckner, Jan C., Lloyd K. Everson, Judith R. OʼFallon, et al.. (1989). Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer. Breast Cancer Research and Treatment. 13(2). 135–142. 19 indexed citations

10.

Poon, Michael A., M. J. OʼConnell, C G Moertel, et al.. (1989). Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.. Journal of Clinical Oncology. 7(10). 1407–1418. 725 indexed citations breakdown →

11.

Brown, Loren D., Roscoe F. Morton, Lloyd K. Everson, et al.. (1988). Evaluation of Fludarabine Phosphate in Patients with Recurrent Glioma. American Journal of Clinical Oncology. 11(5). 586–588. 15 indexed citations

12.

Ingle, James N., Lloyd K. Everson, Harry S. Wieand, et al.. (1988). Randomized trial of observation versus adjuvant therapy with cyclophosphamide, fluorouracil, prednisone with or without tamoxifen following mastectomy in postmenopausal women with node-positive breast cancer.. Journal of Clinical Oncology. 6(9). 1388–1396. 35 indexed citations

13.

Edmonson, J H, James E. Krook, George D. Malkasian, et al.. (1987). Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecologic Oncology. 28(1). 20–24. 40 indexed citations

14.

Ingle, James N., James E. Krook, Lloyd K. Everson, et al.. (1986). Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer.. Journal of Clinical Oncology. 4(2). 178–185. 121 indexed citations

15.

Buroker, T, C G Moertel, Thomas R. Fleming, et al.. (1985). A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.. Journal of Clinical Oncology. 3(12). 1624–1631. 90 indexed citations

16.

Krook, James E., James R. Jett, Thomas R. Fleming, et al.. (1985). A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.. Journal of Clinical Oncology. 3(6). 842–848. 13 indexed citations

17.

Ingle, James N., Stephanie Green, S. Fred Brunk, et al.. (1985). Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure. American Journal of Clinical Oncology. 8(4). 275–282. 13 indexed citations

18.

O’Reilly, Richard J., Lloyd K. Everson, John A. Hansen, et al.. (1976). Effects of exogenous interferon in cytomegalovirus infections complicating bone marrow transplantation. Clinical Immunology and Immunopathology. 6(1). 51–61. 15 indexed citations

19.

Everson, Lloyd K., Donald N. Buell, & G. Nicholas Rogentine. (1973). SEPARATION OF HUMAN LYMPHOID CELLS INTO G1, S, AND G2 CELL CYCLE POPULATIONS BY USE OF A VELOCITY SEDIMENTATION TECHNIQUE. The Journal of Experimental Medicine. 137(2). 343–358. 22 indexed citations

20.

Ruddy, Shaun, Lloyd K. Everson, Peter H. Schur, & K. Frank Austen. (1971). HEMOLYTIC ASSAY OF THE NINTH COMPLEMENT COMPONENT: ELEVATION AND DEPLETION IN RHEUMATIC DISEASES. The Journal of Experimental Medicine. 134(3). 259–275. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact